These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15888706)

  • 21. MADIT II (second Multicenter Automated Defibrillator Implantation Trial) debate: risk stratification, costs, and public policy.
    Reynolds MR; Josephson ME
    Circulation; 2003 Oct; 108(15):1779-83. PubMed ID: 14557341
    [No Abstract]   [Full Text] [Related]  

  • 22. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators.
    Hauser RG
    J Am Coll Cardiol; 2005 Jun; 45(12):2022-5. PubMed ID: 15963404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editorial: The economical challenge in the treatment of chronic heart failure: is primary prophylactic implantable cardioverter defibrillator therapy cost-effective in Europe?
    Cowie MR
    Europace; 2009 Oct; 11(10):1407-8; author reply 1408-10. PubMed ID: 19684038
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness in a flat world--can ICDs help the United States get rhythm?
    Goldman L
    N Engl J Med; 2005 Oct; 353(14):1513-5. PubMed ID: 16207856
    [No Abstract]   [Full Text] [Related]  

  • 25. Implantable defibrillators and beta-blockers in patients with left ventricular dysfunction: economic, ethical, and legal considerations.
    Silver MT
    Am Heart J; 2007 Apr; 153(4 Suppl):59-64. PubMed ID: 17394904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medicare coverage for technological innovations.
    Wynia MK; Witlen R
    N Engl J Med; 2004 Aug; 351(7):719-20; author reply 719-20. PubMed ID: 15306678
    [No Abstract]   [Full Text] [Related]  

  • 27. Medicare changes: fairer payments, delay in practice expenses.
    Minn Med; 1997 Sep; 80(9):35. PubMed ID: 9322419
    [No Abstract]   [Full Text] [Related]  

  • 28. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy.
    Belardinelli R; Capestro F; Misiani A; Scipione P; Georgiou D
    Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):818-25. PubMed ID: 17001224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The economic burden of heart failure and implantable cardioverter defibrillators: The value of noninvasive imaging of high-risk patients.
    Chambers MG; Narula J; Cerqueira MD
    J Nucl Cardiol; 2002; 9(5 Suppl):71S-80S. PubMed ID: 12271267
    [No Abstract]   [Full Text] [Related]  

  • 30. Quality of death: implantable cardioverter defibrillators and proactive care.
    Sears SF; Sowell LV; Kuhl EA; Handberg EM; Kron J; Aranda JM; Conti JB
    Pacing Clin Electrophysiol; 2006 Jun; 29(6):637-42. PubMed ID: 16784431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should we afford implantable cardioverter defibrillator therapy?
    Camm AJ
    Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):59. PubMed ID: 16265354
    [No Abstract]   [Full Text] [Related]  

  • 32. Projecting heart failure into bankruptcy in 2012?
    Stevenson LW
    Am Heart J; 2011 Jun; 161(6):1007-11. PubMed ID: 21641344
    [No Abstract]   [Full Text] [Related]  

  • 33. Medicare prescription drug coverage: a very long wait for a very modest benefit.
    Dalen JE; Hartz DJ
    Am J Med; 2005 Apr; 118(4):325-9. PubMed ID: 15808127
    [No Abstract]   [Full Text] [Related]  

  • 34. Implantable cardioverter-defibrillators for primary prevention of sudden death in heart failure: are there enough bangs for the bucks?
    Stevenson LW
    Circulation; 2006 Jul; 114(2):101-3. PubMed ID: 16831996
    [No Abstract]   [Full Text] [Related]  

  • 35. Patient choice: critical for obtaining value.
    Walker R
    Health Aff (Millwood); 2009; 28(3):923. PubMed ID: 19414909
    [No Abstract]   [Full Text] [Related]  

  • 36. Expensive medical technologies and "indication extrapolation": the case of implantable cardioverter-defibrillators.
    Simpson CS; Klein GJ; Hoffmaster B
    Am Heart J; 2000 Sep; 140(3):419-22. PubMed ID: 10966539
    [No Abstract]   [Full Text] [Related]  

  • 37. Medical and pharmacy coverage decision making at the population level.
    Mohr PE; Tunis SR
    J Manag Care Spec Pharm; 2014 Jun; 20(6):547-54. PubMed ID: 24856592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicare coverage for technological innovations.
    Hart S
    N Engl J Med; 2004 Aug; 351(7):719-20; author reply 719-20. PubMed ID: 15309749
    [No Abstract]   [Full Text] [Related]  

  • 39. Implantable cardioverter-defibrillators.
    van Veldhuisen DJ; Voors AA
    N Engl J Med; 2005 May; 352(19):2022-5; author reply 2022-5. PubMed ID: 15892194
    [No Abstract]   [Full Text] [Related]  

  • 40. Implantable cardioverter/defibrillator therapy: the meaning of terms.
    Smith ER
    Can J Cardiol; 2000 Oct; 16(10):1325-6. PubMed ID: 11064309
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.